Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd lifted its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 16.8% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,222,695 shares of the company's stock after buying an additional 1,329,319 shares during the period. Teva Pharmaceutical Industries makes up approximately 1.0% of AustralianSuper Pty Ltd's holdings, making the stock its 23rd largest position. AustralianSuper Pty Ltd owned approximately 0.81% of Teva Pharmaceutical Industries worth $203,268,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in TEVA. AQR Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth about $262,000. Cetera Investment Advisers lifted its position in Teva Pharmaceutical Industries by 83.9% in the second quarter. Cetera Investment Advisers now owns 60,868 shares of the company's stock valued at $989,000 after purchasing an additional 27,765 shares during the period. Creative Planning lifted its position in Teva Pharmaceutical Industries by 4.5% in the third quarter. Creative Planning now owns 42,815 shares of the company's stock valued at $772,000 after purchasing an additional 1,863 shares during the period. Claro Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the third quarter valued at about $52,000. Finally, Blue Trust Inc. lifted its position in Teva Pharmaceutical Industries by 40.1% in the third quarter. Blue Trust Inc. now owns 14,619 shares of the company's stock valued at $263,000 after purchasing an additional 4,185 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of recent analyst reports. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, January 30th. UBS Group reduced their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a report on Monday, October 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $23.57.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded up $0.30 during mid-day trading on Tuesday, reaching $16.55. 19,455,768 shares of the company's stock were exchanged, compared to its average volume of 13,130,188. The company has a quick ratio of 0.61, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The company has a 50-day simple moving average of $19.93 and a two-hundred day simple moving average of $18.50. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80. The company has a market cap of $18.74 billion, a price-to-earnings ratio of -11.41, a PEG ratio of 1.39 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.